This 2023 systematic review analyzed 12 completed phase III and IV clinical trials registered on ClinicalTrials.gov, focusing on nutraceutical interventions for Nonalcoholic Fatty Liver Disease (NAFLD). The majority of studies investigated vitamin D (26.7%) and omega-3 fatty acids (20.0%), with others examining caffeine, chlorogenic acid, ginger, phosphatidylcholine, Trigonella foenum-graecum seed
